Mhyosphere PCV ID Euroopan unioni - islanti - EMA (European Medicines Agency)

mhyosphere pcv id

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svín - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Lung test gas CO/He Linde (Lung test gas CO (HE) Aga) Lyfjagas undir þrýstingi 0,28 % Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

lung test gas co/he linde (lung test gas co (he) aga) lyfjagas undir þrýstingi 0,28 %

linde sverige ab - carbonei monoxidum; helium - lyfjagas undir þrýstingi - 0,28 %

Sandimmun Innrennslisþykkni, lausn 50 mg/ml Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

sandimmun innrennslisþykkni, lausn 50 mg/ml

novartis healthcare a/s - ciclosporinum inn - innrennslisþykkni, lausn - 50 mg/ml

Emla (EMLA) Lyfjaplástur 25+25 mg/plástur Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

emla (emla) lyfjaplástur 25+25 mg/plástur

aspen pharma trading limited - lidocainum inn; prilocainum inn - lyfjaplástur - 25+25 mg/plástur

Niontix Lyfjagas, fljótandi 100% Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

niontix lyfjagas, fljótandi 100%

linde sverige ab - dinitrogenii oxidum - lyfjagas, fljótandi - 100%

Monoprost Augndropar, lausn í stakskammtaíláti 50 míkróg/ml Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

monoprost augndropar, lausn í stakskammtaíláti 50 míkróg/ml

laboratoires thea* - latanoprostum inn - augndropar, lausn í stakskammtaíláti - 50 míkróg/ml

Livostin Nefúði, dreifa 0,5 mg/ml Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

livostin nefúði, dreifa 0,5 mg/ml

mcneil sweden ab - levocabastinum hýdróklóríð - nefúði, dreifa - 0,5 mg/ml

Livostin Augndropar, dreifa 0,5 mg/ml Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

livostin augndropar, dreifa 0,5 mg/ml

mcneil sweden ab - levocabastinum hýdróklóríð - augndropar, dreifa - 0,5 mg/ml

Livopan Lyfjagas undir þrýstingi 50/50 % Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

livopan lyfjagas undir þrýstingi 50/50 %

linde sverige ab - dinitrogenii oxidum; oxygenium - lyfjagas undir þrýstingi - 50/50 %

SmofKabiven extra Nitrogen Innrennslislyf, fleyti Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

smofkabiven extra nitrogen innrennslislyf, fleyti

fresenius kabi ab - alaninum inn; argininum inn; glycine; histidinum inn; isoleucinum inn; leucinum inn; lysinum asetat; methioninum inn; phenylalaninum inn; prolinum inn; serinum inn; taurinum inn; threoninum inn; tryptophanum inn; tyrosinum inn; valinum inn; calcii chloridum dihydricum inn; natrii glycerophosphas; magnesium sulfate heptahydrate; kalii chloridum; natrii acetas; zinc sulphate heptahydrate; glucose monohydrate; soiae oleum raffinatum; triglycerides medium chain; olivae oleum raffinatum; fish oil rich in omega-3 acids - innrennslislyf, fleyti